Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM
Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.
EP: 1.Biomarkers in Multiple Myeloma (MM): Overview
EP: 2.Role of t(11;14) Translocation in Patients with MM
Now Viewing
EP: 3.Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM
EP: 4.Emerging Biomarkers in Multiple Myeloma
EP: 5.Testing for Biomarkers in Multiple Myeloma
EP: 6.Future Perspectives in Biomarker Identification and Testing in MM
Related Videos
Related Content
